Keryx Biopharma files for EU approval of Zerenex

Keryx Biopharma files for EU approval of Zerenex


US drugmaker Keryx Biopharmaceuticals has submitted a Marketing Authorization Application to the European…

EuropeKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationZerenex

US nephrologists views on prescribing Roche’s Mircera


Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

Keryx Biopharma rockets on new Zerenex data and plans to file for approval


USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

News briefs: Roche's dalcetrapib; Coherus/Daiichi deal; Mercury Pharma; AEterna Zentaris


Swiss drug major Roche (ROG: SIX) saw its shares drop 4.5% to 159.30 Swiss francs by around midday yesterday,…

AEterna ZentarisBiotechnologyCoherus BioSciencesDaiichi SankyodalcetrapibGenericsKeryx BiopharmaceuticalsLicensingMercury PharmaMergers & AcquisitionsperifosinePharmaceuticalResearchRoche

AEterna Zentaris and Keryx shares tank as cancer drug flops in Ph III


Canadian drug developer AEterna Zentaris (TSX: AEZ) and US licensee Keryx Pharmaceutical (Nasdaq: KERX)…

AEterna ZentarisKeryx BiopharmaceuticalsLicensingNephrology and HepatologyOncologyperifosinePharmaceuticalResearchZerenex

Drug manufacturing industry on an explosive journey, new study notes, highlighting Abbott and Keryx


It is needless to say that the drug manufacturing is a multi-billion dollar industry that is set to experience…

Abbott LaboratoriesFinancialKeryx BiopharmaceuticalsMergers & AcquisitionsPharmaceutical



Back to top